The Russian Direct Investment Fund (RDF) and Indian pharmaceutical company Panacea Biotech have announced the launch of the Sputnik 5 Covid-19 vaccine in India. The first batch of Covid-19 wax, manufactured at Panesia Biotech’s manufacturing facility in Buddy, Himachal Pradesh, will be sent to the Gamelia Institute in Russia for quality testing. RDF and Panacea Biotech said in a joint statement that full production of the vaccine would begin in the coming months. As announced in April, RDF and Panacea have agreed to produce 100 million doses of the Sputnik 5 vaccine each year.”The launch of production in India in collaboration with Panacea Biotech marks an important step in helping the country fight the epidemic,” said Kirill Dimitriev, RDF Chief Executive.
He said the production of Sputnik V would help support the Indian authorities’ efforts to survive the acute phase of the coronavirus as soon as possible. He added that the vaccine would be exported to other parts of the world to prevent the spread of the virus. “This is an important step when we start production of Sputnik V. With RDF, we hope to help people across the country and around the world return to normalcy, ”said Rajesh Jain, Panesia Biotech MD. On April 12, 2021, the Sputnik vaccine was approved for immediate use in India. The vaccine has been available in the country since May 14.